Clinical Trials Logo

B-lymphoid Malignancies clinical trials

View clinical trials related to B-lymphoid Malignancies.

Filter by:
  • None
  • Page 1

NCT ID: NCT03056339 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Start date: June 21, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

If you are reading and signing this form on behalf of a potential participant, please note: Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. The goal of this clinical research study is to learn if giving genetically changed immune cells, called CAR-NK cells, after chemotherapy will improve the disease in stem cell transplant patients with relapsed (has returned) and/or refractory (has not responded to treatment) B-cell lymphoma or leukemia. Also, researchers want to find the highest tolerable dose of CAR-NK cells to give to patients with relapsed or refractory B-cell lymphoma or leukemia. The safety of this treatment will also be studied. This is an investigational study. The making of and infusion of genetically changed NK cells and the drug AP1903 (if you receive it, explained below) are not FDA approved or commercially available for use in this type of disease. They are currently being used for research purposes only. The chemotherapy drugs in this study (fludarabine, cyclophosphamide, and mesna) are commercially available and FDA approved. Up to 36 patients will take part in this study. All will be enrolled at MD Anderson.

NCT ID: NCT00446342 Completed - Multiple Myeloma Clinical Trials

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

Start date: February 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.